Diabetes products were once Becton Dickinson’s core business and have been key to its corporate identity for over a century. These products are now independent. BD Derivation is done On Friday, the assets of its pre-diabetic assets allowed the business to forge its own path under the new name Embecta.
Under the terms of the deal, BD shareholders will receive one share of Embecta for every five shares of BD they own as of March 22. The Emecta spin-off severed all financial ties to BD, which now holds no ownership stake in its pre-diabetic business. Parsippany, N.J.-based Embecta began trading on the Nasdaq on Friday under the ticker “EMBC.”
BD has been pursuing a corporate growth strategy known as “BD 2025”.When medical product giants are number one Announced in May last year plans to spin off its diabetes business from its parent company into a separate public company, BD CEO and President Tom Polen said the move is part of BD’s 2025 plan and will give each company the flexibility and focus to grow independently. BD’s board approved the spin-off in February.
Emecta Diversifies BD’s Business Compared to Maxwell Becton and Fairleigh Dickinson establish a company In 1897, glass syringes were initially sold. Acquisitions have added new products and lines of business over the years. Under its current structure, the Franklin Lakes, NJ-based company operates three business units: BD Medical, BD Life Sciences and BD Interventional.
Diabetes Care is part of BD Medical.according to Embecta’s financial documents, the diabetes products business posted a profit of $415 million in the 12 months ended September 30, 2021, on revenue of more than $1.1 billion. The United States is Embecta’s largest market, accounting for more than half of its global sales.according to a BD Investor Presentation, the business produces 8 billion medical devices for approximately 30 million patients worldwide. Embecta is led by CEO Devdatt Kurdikar, former global president of BD Diabetes Care.
“While BD is proud of its heritage in diabetes care, we are equally delighted to see Embecta carry on the legacy as a newly independent public company,” Polen said in a prepared statement. “Going forward, each of our organizations will be able to focus on investment and innovation in their respective core businesses, supporting our customers and the patients they serve, driving strategic growth and enhancing long-term shareholder value.”
Photo: Hero Images, Getty Images
